SciELO - Brasil - Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em
cardiologia Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em …

In 2013, the Brazilian Cardiology Society published the “Brazilian Guidelines on Antiplatelet
and Anticoagulant Agents in Cardiology.” Over the past years, new studies have been …

Background Despite numerous randomized clinical trials (RCT), data regarding the efficacy
of antiplatelet and anticoagulant combinations are still conflicting. We aimed to analyze …

Antiplatelet therapy is the cornerstone for both primary and secondary prevention therapies
for ischemic events resulting from coronary atherosclerotic disease. Dual antiplatelet therapy …

Antiplatelet agents are a cornerstone of therapy for patients with atherosclerotic vascular
disease. There is presently a lack of comprehensive guidelines focusing on the use of …

Antiplatelet therapy (APT) has become an important tool in the treatment and prevention of
atherosclerotic events, particularly those associated with coronary artery disease. A large …

Antiplatelet and anticoagulant drugs work at different places in the coagulation system.
Antiplatelet drugs are usually indicated in patients with atherosclerosis. Anticoagulant drugs …

Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic
events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT …

The role of aspirin and other platelet-active drugs in the treatment and prevention of
atherothrombosis has been reviewed recently by the Sixth American College of Chest …

Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the
cornerstone of the pharmacological treatment and prevention of atherothrombotic diseases …